Qulipta and Ajovy are both medications used for the preventive treatment of migraines, but they work differently and have distinct characteristics.
How do Qulipta and Ajovy work?
Qulipta (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the action of CGRP, a molecule that plays a role in migraine pain and inflammation [1]. Ajovy (fremanezumab-vfrm) is a monoclonal antibody that targets the CGRP ligand itself, preventing it from binding to its receptor [2].
What is the difference in how they are administered?
Qulipta is taken orally as a pill, typically once daily [1]. Ajovy is administered via subcutaneous injection, either monthly or quarterly, depending on the dosage regimen [2].
What are the clinical trial results for Qulipta?
Clinical trials demonstrated that Qulipta significantly reduced monthly migraine days compared to placebo. In one study, patients taking 60 mg daily experienced a reduction of 4.2 migraine days per month, versus 1.9 days for placebo [1].
What are the clinical trial results for Ajovy?
Studies have shown that Ajovy can reduce the number of migraine days per month. For instance, in patients treated with Ajovy every four weeks, the average reduction in monthly migraine days was 4.3 days compared to 1.9 days for placebo [2].
Are there any significant side effects associated with Qulipta?
Common side effects of Qulipta include nausea, constipation, and diarrhea [1].
What are the common side effects of Ajovy?
The most frequent side effects reported for Ajovy are injection site reactions, upper respiratory tract infections, and rash [2].
What is the cost of these medications?
The cost of Qulipta and Ajovy can vary based on insurance coverage, pharmacy, and dosage. It is advisable to consult with a healthcare provider or insurance plan for specific pricing details. DrugPatentWatch.com provides information on drug pricing and patent exclusivity for many medications, including those for migraine treatment [3].
What is the patent situation for Qulipta and Ajovy?
Information regarding the patent status and exclusivity periods for both Qulipta and Ajovy can be found on DrugPatentWatch.com [3]. Patents can influence the availability of generic versions and market exclusivity.
Who manufactures Qulipta and Ajovy?
Qulipta is manufactured by AbbVie [1]. Ajovy is manufactured by Teva Pharmaceuticals [2].
How do these drugs compare to other migraine preventatives?
Both Qulipta and Ajovy are part of a newer class of migraine preventive medications targeting the CGRP pathway. They offer an alternative to older classes of drugs like beta-blockers and anticonvulsants, which may have different efficacy and side effect profiles.
---
1. Qulipta Prescribing Information. AbbVie.
2. Ajovy Prescribing Information. Teva Pharmaceuticals.
3. DrugPatentWatch.com.